Granules India Limited — Investor Meet, 13-11-2024: Analysts/Institutional Investor Meet/Con. Call Updates

**Financial Performance:** Granules India Limited reported Q2 FY25 revenues of INR 9,666 million, a decline of 19% year-over-year and 18% compared to Q1 FY25. Despite the drop in sales, the company achieved gross margins of 62%, up from 51.7% in Q2 FY24, attributed to a favorable sales mix with higher contribution from formulations and reduced raw material costs. EBITDA for the quarter was INR 2,033 million with an EBITDA margin of 21%, reflecting an increase from 17.9% a year earlier but a slight decrease from Q1 FY25’s margin.

**Future Outlook and Growth Drivers:** Management remains optimistic about near-term growth, primarily driven by new product launches in the CNS and ADHD segments, which are expected to mitigate the impact from the Gagillapur facility's temporary shutdown. The new formulations facility at Genome Valley is also progressing, targeting volume increases and additional product commercialization in the upcoming quarters, contributing to long-term growth.

**Order Book and Operational Updates:** Following the voluntary pause in operations due to FDA inspection, the company resumed production in October, shifting focus to new filings and ensuring the continuity of operations. Three approvals are pending from the Gagillapur facility, expected in Q4 FY25.

**Analyst Q&A Insights:** Analysts raised concerns regarding revenue projections and remediation costs from FDA observations, which are anticipated to total about $2 million this fiscal year. Management expressed confidence in resolving FDA-related issues expeditiously and highlighted operational recovery in Q3, with lost sales projected to be less than in Q2.

**Market or Regulatory Updates:** The company addressed challenges including supply chain pressures and inventory buildup affecting demand, particularly for paracetamol. Management detailed ongoing improvements in operational processes to align with regulatory compliance and quality standards.

**Strategic Focus Areas:** Management emphasized a continued focus on innovation with a planned R&D budget of INR 524 million in Q2 FY25 and ongoing development in critical areas, including oncology and sustainable practices within R&D.

**Investor Insight:** Financial health appears stable with a gradual recovery in sales anticipated. The strategic initiatives in product development and operational compliance could position Granules favorably in the market, offering potential for a ‘buy’ position, depending on the realization of upcoming growth drivers amidst current operational challenges.